Norges Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Norges Bank’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,500	Closed	-$423K	–	2180
2020 Q4	$423K	Hold	12,500	–	–	﹤0.01%	2086
2020 Q3	$313K	Hold	12,500	–	–	﹤0.01%	2104
2020 Q2	$422K	Buy	+12,500	New	+$399K	﹤0.01%	2056

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Norges Bank's ORIC Position: Q1 2021 in Review

Norges Bank sold out of Oric Pharmaceuticals (ORIC) in Q1 2021, closing a stake of 12,500 shares — an estimated $423K sold.

Norges Bank first reported a position in ORIC in Q2 2020 and held it in 3 quarters. The position peaked at $423K in Q4 2020. 82 funds tracked by Wall St. Rank hold ORIC as of Q1 2021.

Norges Bank reported no remaining Oric Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Norges Bank sold 12,500 Oric Pharmaceuticals shares in Q1 2021, an estimated $423K.
Norges Bank first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 3 quarters.
Norges Bank's Oric Pharmaceuticals position peaked at $423K in Q4 2020.
82 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.